The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Evaluating organ preservation in node-negative low rectal cancer
Vanessa Wookey, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses a Phase II investigator-initiated trial (NCT03548961) evaluating the feasibility of local excision following neoadjuvant FOLFOX in patients with node-negative low rectal cancer (RC). Organ preservation was possible in a majority of patients who received neoadjuvant chemotherapy and local excision. This approach suggests potential for organ preservation in node negative low RC, warranting further investigation to optimize outcomes and quality of life. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
